Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients.
Adjuvant therapy
Breast cancer
Dual blockade
HER2
Pertuzumab
Trastuzumab
Journal
Cancer treatment reviews
ISSN: 1532-1967
Titre abrégé: Cancer Treat Rev
Pays: Netherlands
ID NLM: 7502030
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
26
06
2019
revised:
22
11
2019
accepted:
25
11
2019
pubmed:
13
12
2019
medline:
24
1
2020
entrez:
13
12
2019
Statut:
ppublish
Résumé
The use of adjuvant pertuzumab in HER2-positive early-stage breast cancer has recently been approved by the EMA on the basis of data from the APHINITY trial. Accordingly, we have produced this opinion article with the aim of putting the study data in perspective against other add-on therapeutic strategies, to clarify methodological or statistical doubts about the study, and to define the population of high-risk patients with hormone receptor-negative breast cancer that we agree, in general, should be treated. With this approval, physicians must be well prepared to place the APHINITY study data in context. It is now up to each country to ratify the EMA-approved indications and to agree on reimbursement, and doctors must optimize their use based on knowledge and discussion with patients.
Identifiants
pubmed: 31830538
pii: S0305-7372(19)30165-3
doi: 10.1016/j.ctrv.2019.101944
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Antineoplastic Agents, Immunological
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
pertuzumab
K16AIQ8CTM
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101944Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.